Orathecin

Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by SuperGen (now Astex Pharmaceuticals, Inc.; a member of the Otsuka Group). Contents 1 History 2 Synthesis 3 Use as Anti-Cancer Drug 4 References History On January 27, 2004, SuperGen announced that it has completed the submission of an NDA for rubitecan to the US FDA,[2] and was accepted for filing on March 2004.[3] In January 2005, and under the direction of then-C... [wikipedia]